Literature DB >> 27049967

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.

Ronald D Alvarez1, Ursula A Matulonis2, Thomas J Herzog3, Robert L Coleman4, Bradley J Monk5, Maurie Markman6.   

Abstract

Entities:  

Keywords:  Platinum sensitive/resistant; Recurrent ovarian cancer

Mesh：

Substances：

Year:  2016        PMID： 27049967     DOI： 10.1016/j.ygyno.2016.03.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  8 in total

Review 1.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

Review 2.  Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Authors:  M Buechel; T J Herzog; S N Westin; R L Coleman; B J Monk; K N Moore
Journal:  Ann Oncol       Date:  2019-05-01       Impact factor: 32.976

Review 3.  Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.

Authors:  L E Dockery; C C Gunderson; K N Moore
Journal:  Onco Targets Ther       Date:  2017-06-19       Impact factor: 4.147

4.  Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.

Authors:  Kristen Starbuck; Linah Al-Alem; David A Eavarone; Silvia Fatima Hernandez; Chiara Bellio; Jillian M Prendergast; Jenna Stein; Daniel T Dransfield; Bianca Zarrella; Whitfield B Growdon; Jeff Behrens; Rosemary Foster; Bo R Rueda
Journal:  Oncotarget       Date:  2018-05-01

5.  Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

Authors:  John B Liao; William R Gwin; Renata R Urban; Katie M Hitchcock-Bernhardt; Andrew L Coveler; Doreen M Higgins; Jennifer S Childs; Hania N Shakalia; Ron E Swensen; Sasha E Stanton; Anna V Tinker; Tanya A Wahl; Richard G Ancheta; Kathryn F McGonigle; James Y Dai; Mary L Disis; Barbara A Goff
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

6.  Predicting Long-Term Prognoses and Grading Platinum Sensitivity Using a Novel Progression-Free Interval Criterion in Ovarian Clear Cell Carcinoma: A Multi-Institutional Cohort Study.

Authors:  Cheng-Yang Chou; Wen-Fang Cheng; Min-Yu Chen; Hao Lin; Chih-Ming Ho; Yao-Ching Hung; Lee-Wen Huang; Po-Hui Wang; Mu-Hsien Yu; Yu-Fang Huang
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

Review 7.  PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Authors:  Mekonnen Sisay; Dumessa Edessa
Journal:  Gynecol Oncol Res Pract       Date:  2017-11-29

8.  Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.

Authors:  Charles-André Philip; Ido Laskov; Marie-Claude Beauchamp; Maud Marques; Oreekha Amin; Joanna Bitharas; Roy Kessous; Liron Kogan; Tahira Baloch; Walter H Gotlieb; Amber Yasmeen
Journal:  BMC Cancer       Date:  2017-09-08       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.